SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT03941782

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

INST UNM 1601: Compassionate Use of BYL 719 Alpelisib

This is a compassionate use protocol of BYL719 (alpelisib) treatment for a single patient with locally advanced lymphangioma positive PI3K alpha H1047R mutation.

NCT03941782 Lymphangioma
MeSH:Lymphangioma
HPO:Lymphangioma

1 Interventions

Name: Alpelisib

Description: As a single agent, alpelisib will be administered at a starting dose of 350 mg orally once daily on a continuous dosing schedule and can be adjusted for toxicity per the recommendations in this protocol. No pretreatment will be given prior to the medication.
Type: Drug



There is one SNP

SNPs


1 H1047R

Compassionate Use of BYL 719 Alpelisib This is a compassionate use protocol of BYL719 (alpelisib) treatment for a single patient with locally advanced lymphangioma positive PI3K alpha H1047R mutation. --- H1047R ---



HPO Nodes


HPO: